Founded in 2015 by a team responsible for the FDA’s approval of the world’s first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies. Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.

Employee Rating

0More
TypePrivate
HQSeattle, US
Founded2015
Websitealpineimmunesciences.com
Alpine Immune Sciences was founded in 2015 and is headquartered in Seattle, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Alpine Immune Sciences

Mitchell H. Gold

Mitchell H. Gold

Executive Chairman & CEO
Mark Litton

Mark Litton

President & Chief Operating Officer
Stanford Peng

Stanford Peng

Executive VP of R&D, Chief Medical Officer
Kristine Swiderek

Kristine Swiderek

Senior VP of Research
Paul Rickey

Paul Rickey

CFO
Show more

Alpine Immune Sciences Office Locations

Alpine Immune Sciences has an office in Seattle
Seattle, US (HQ)
200 Elliott Avenue West
Show all (1)
Report incorrect company information

Alpine Immune Sciences Financials and Metrics

Summary Metrics

Founding Date

2015

Alpine Immune Sciences total Funding

$49.3 m

Alpine Immune Sciences latest funding size

$48 m

Time since last funding

3 years ago

Alpine Immune Sciences investors

Alpine Immune Sciences's latest funding round in June 2016 was reported to be $48 m. In total, Alpine Immune Sciences has raised $49.3 m
View all funding rounds

Alpine Immune Sciences Revenue

Alpine Immune Sciences's revenue was reported to be $1.73 m in FY, 2017 which is a 41.3% decrease from the previous period.
USD

EBIT (Q3, 2018)

(12.4m)

Cash (30-Sep-2018)

11.5m
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

492.0k3.0m1.7m

Revenue growth, %

500%(41%)

General and administrative expense

441.0k1.1m6.1m

R&D expense

422.0k3.0m10.6m
Quarterly
USDQ3, 2015Q1, 2017

General and administrative expense

1.8m2.8m

R&D expense

4.3m2.8m

Operating expense total

6.1m5.5m

EBIT

(6.1m)(9.0m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

25.0m11.8m8.0m

Prepaid Expenses

432.0k36.0k1.3m

Current Assets

87.7m11.9m82.5m

PP&E

223.0k740.0k1.1m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

100.5m57.6m16.0m15.4m16.2m12.9m27.5m12.0m7.4m3.6m11.5m

Current Assets

101.1m93.6m80.7m74.2m67.0m52.9m49.6m88.1m78.0m71.8m63.1m

PP&E

1.1m1.1m1.2m1.3m

Total Assets

101.2m93.8m80.9m74.6m67.3m53.0m49.6m90.8m80.7m73.1m64.5m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(22.8m)(31.5m)(7.8m)

Depreciation and Amortization

241.0k

Accounts Payable

65.0k927.0k66.0k

Cash From Operating Activities

(19.2m)(26.3m)(16.6m)
Quarterly
USDY, 2018

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Alpine Immune Sciences Online and Social Media Presence

Embed Graph
Report incorrect company information

Alpine Immune Sciences Blogs

Alpine Immune Sciences Announces $25 Million Private Placement

Alpine Immune Sciences Announces $25 Million Private Placement Content Import Wed, 01/16/2019 - 07:02 Alpine Immune Sciences Announces $25 Million Private Placement January 16, 2019 This release is a backfill from a News Wire General …

Alpine Immune Sciences Showcases Key Preclinical Data at 60th American Society of Hematology Annual Meeting and Exposition

Company’s Lead Program, ALPN-101, Demonstrates Activity in Animal Models of Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis Alpine Also Highlights Potential for Transmembrane and Secreted Immunomodulatory Proteins to Enhance Activity of Engineered T Cells Company Adds Distinguished

Alpine Immune Sciences Announces ALPN-101 Data to be Included in Oral Presentation at 60th American Society of Hematology Annual Meeting and Exposition

SEATTLE --(BUSINESS WIRE)--Nov. 29, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced pre-clinical data from its lead autoimmune/inflammatory

Alpine Immune Sciences Advances Oncology Programs with New ALPN-202 Preclinical Data and Key Additions to Scientific Advisory Board

ALPN-202 Preclinical Data Presented at the Society for Immunotherapy of Cancer’s ( SITC ) 33 rd Annual Meeting Supports First-In-Class Triple Mechanism of Action for the Treatment of Cancer Company Strengthens Scientific Advisory Board with Slate of Oncology Leaders SEATTLE --(BUSINESS WIRE)--Nov.

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results Content Import Thu, 11/08/2018 - 16:38 Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2018 Financial Results November 8, 2018 This re…

Alpine Immune Sciences to Present at Two Upcoming Investor Conferences

SEATTLE --(BUSINESS WIRE)--Nov. 5, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced the company will participate in two upcoming investor
Show more

Alpine Immune Sciences Company Life and Culture

Report incorrect company information

Alpine Immune Sciences Frequently Asked Questions

  • When was Alpine Immune Sciences founded?

    Alpine Immune Sciences was founded in 2015.

  • Who are Alpine Immune Sciences key executives?

    Alpine Immune Sciences's key executives are Mitchell H. Gold, Mark Litton and Stanford Peng.

  • What is Alpine Immune Sciences revenue?

    Latest Alpine Immune Sciences annual revenue is $1.7 m.

  • Who are Alpine Immune Sciences competitors?

    Competitors of Alpine Immune Sciences include GTx, Rexahn Pharmaceuticals and Burzynski Research Institute.

  • Where is Alpine Immune Sciences headquarters?

    Alpine Immune Sciences headquarters is located at 200 Elliott Avenue West, Seattle.

  • Where are Alpine Immune Sciences offices?

    Alpine Immune Sciences has an office in Seattle.

  • How many offices does Alpine Immune Sciences have?

    Alpine Immune Sciences has 1 office.